Abigail Brooks, MA

Despite decreasing death rates, an analysis of GBD 2021 data highlights the increasing incidence of cirrhosis and other chronic liver diseases.

HCV screening in pregnant women increased following universal screening guidelines, but the proportion of women who were ever tested remained low.

From 1990-2021, the ASIR, ASMR, and age-standardized DALY rate of chronic kidney disease increased.

The analysis of US healthcare claims data suggests noninvasive methods are being used more often than liver biopsies for the diagnosis of MASH.

Patients with PBC and severe pruritus had worse HRQoL, greater rates of depression, and more sleep interference than those with mild/moderate pruritus.

The strategy detailed in the guidance aids the early identification of infants with biliary atresia and is intended for use between 2 and 4 weeks of life.

Low and high second-trimester eGFR values were linked to adverse pregnancy outcomes, including preeclampsia, preterm birth, low birth weight, and fetal loss.

The multidisciplinary care model included 7 co-located specialists who aided patient education, lifestyle intervention, and drug therapy strategies for MASH.

Amneal Pharmaceuticals launched mesalamine 800 mg delayed-release tablets for UC and received FDA approval for various lenalidomide doses for blood cancers.

Chemomab completed an end-of-phase 2 meeting with the FDA and has aligned on the design of a phase 3 registration study for nebokitug (CM-101) in PSC.

HDV RNA-positive patients were more often diagnosed with advanced liver fibrosis and had a 4.7-fold greater risk of severe liver-related outcomes.

A patient with decompensated liver cirrhosis treated with Namodenoson under a compassionate use program experienced improvements in disease at 20 months.

Younger age, low knowledge of HBV sequelae, and high perceived HBV stigma were linked to lower medication adherence in Korean American patients.

Female dialysis patients had a greater risk of infection- and withdrawal-related mortality, while men were more likely to die from cardiovascular disease and cancer.

The analysis of NHANES data found 11.3% of adolescents have suspected MASLD. Estimates were greater for those with elevated ALT.

Greater levels of RC were linked to increased CKD risk and progression to ESRD in patients with type 2 diabetes-related kidney disease.

In patients with HCV-related compensated cirrhosis, DAA treatment was linked to lower HCC risk than no treatment but similar risk to a historical IFN cohort.

Lee explains study findings suggesting MetALD classification should be based on ≥ 3 cardiometabolic risk factors rather than just alcohol intake.

Patients with adenomas had a greater risk of colorectal cancer, and advanced adenomas were linked to a greater risk of cancer-related and all-cause mortality.

Higher Dietary Inflammatory Index scores were associated with an increased risk of developing chronic liver disease and cirrhosis progression.

GLP-1 RA use was associated with a lower risk of major cardiovascular events, clinically significant portal hypertension, and all-cause mortality in MASLD.

The analysis of 2004-2024 Google Trends data revealed varying levels of public interest in IgAN, MD, FSGS, LN, and DN.

Exposure to aspirin and NSAIDs was linked to a reduced risk of cancer incidence and overall mortality in patients with chronic liver diseases.

Barnes explains the significance of having mirikizumab as a treatment option for Crohn’s disease and reviews new VIVID-2 open-label extension data.

The Fast Track Designation was granted to Biodexa Pharmaceuticals’ eRapa based on phase 2 data showing its safety and tolerability in adults with FAP.

Study findings suggest children with documented SARS-CoV-2 infection face an increased risk of GI tract symptoms than those without the infection.

Findings from the VIVID-2 open-label extension study in patients with CD highlight long-term clinical and endoscopic outcomes with mirikizumab.

The genetically edited pig kidney was provided by eGenesis and successfully transplanted into a 66-year-old male patient with end-stage kidney disease.

GLP-1 RA use was linked to a reduced risk of alcohol-associated liver disease, lower rates of hepatic decompensation, and improved survival.

Findings highlight the need for early frailty screening in dialysis patients and the implementation of appropriate interventions to improve outcomes.